Glaukos Shares Surge on Triple Dose of Positive News

Glaukos Corporation has ignited investor enthusiasm with a powerful trifecta of developments, propelling its stock to impressive gains. The equity advanced nearly 18% within a single week, fueled by record-breaking financial results, an upward revision of its financial outlook, and a significant regulatory approval from the U.S. Food and Drug Administration. The central question for the market is whether this powerful momentum is sustainable.

A pivotal development occurred on October 20, when the FDA granted approval for Epioxa. This treatment is recognized as the first and only incision-free therapy for keratoconus. The Read more...